This review highlights the interplay between paraneoplastic cells and platelets in driving thrombotic risk in cancer patients.
Answers are grounded in this paper and cite their sources.
May refine thrombosis risk assessment in cancer; leaves open platelet-targeted interventions for prospective trials.
Hematologic malignancies and solid tumors increase the risk of venous and arterial thrombosis and contribute greatly to patient morbidity and mortality. Thrombosis occurs when the intricate balance of circulating antithrombotic and prothrombotic blood elements are disrupted. In recent years, the interplay between paraneoplastic cells and platelets has become apparent, with a change in platelet phenotype causing dysregulated platelet activity. This review discusses mechanism of thrombosis in cancer, evidence for using drug therapy, and exciting research efforts to understand and hopefully control aberrant thrombotic events in patients with cancer.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: